Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer

被引：0
|
作者：
Borghaei, H. [1 ]
Shaw, J. [2 ]
Pundole, X. [2 ]
Balasubramanian, A. [2 ]
Anderson, E. [2 ]
Bebb, G. [2 ]
Jiang, T. [2 ]
Pastel, M. [2 ]
Martinez, P. [2 ]
Ramalingam, S. [3 ]
机构：
[1] Fox Chase Canc Ctr, Philadelphia, PA USA
[2] Amgen Inc, Thousand Oaks, CA 91320 USA
[3] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2023年 / 18卷 / 11期
关键词：
small cell lung cancer; recent treatment patterns; impact of PD-L1 inhibitors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P2.17-01
引用
收藏
页码：S377 / S378
页数：2
相关论文
共 50 条
  • [21] Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [22] Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective
    Prabhakaran, S.
    Russell, P. A.
    Farrall, A. L.
    Asadi, K.
    Barrett, W.
    Cooper, C.
    Cooper, W.
    Duhig, E. E.
    Egan, M.
    Fox, S.
    Godbolt, D.
    Gupta, S.
    Cotton, S.
    Leslie, C.
    Leong, T.
    Moffat, D.
    Qiu, M.
    Sivasubramaniam, V.
    Snell, C.
    Skerman, J.
    Walsh, M.
    Whale, K.
    Klebe, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S479 - S479
  • [23] Real-world outcomes in extensive-stage small cell lung cancer with PD-L1 inhibitors in China
    Meng, X.
    Peng, J.
    Li, S.
    Feng, H.
    Meng, R.
    Zhang, L.
    Liu, X.
    Yu, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1420 - S1421
  • [24] A Chinese multicenter, real-world study of PD-L1 inhibitors in extensive stage small cell lung cancer
    Peng, J.
    Meng, R.
    Liu, X.
    Zhang, L.
    Wang, L.
    Feng, R.
    Feng, H.
    Huang, Z.
    Yao, D.
    Li, X.
    Liu, N.
    Tan, B.
    Li, S.
    Yu, J.
    Meng, X.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S135 - S135
  • [25] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [26] Real-world treatment patterns and outcomes of patients with small cell lung cancer progressing after 2 lines of therapy
    Coutinho, Anna D.
    Shah, Manan
    Lunacsek, Orsolya E.
    Eaddy, Michael
    Willey, Joanne P.
    LUNG CANCER, 2019, 127 : 53 - 58
  • [27] Real-world treatment patterns before and after receiving PD-l1 test results in patients with advanced non-small cell lung cancer (aNSCLC)
    Ge, Wenzhen
    Antonia, Scott
    Wu, Ning
    Pouliot, Jean-Francois
    Dietz, Hilary
    Jalbert, Jessica
    Quek, Ruben Gw
    Harnett, James
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 111 - 112
  • [28] Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)
    Staib, J.
    Sudarsanam, S.
    Byfield, S. Dacosta
    Kennedy, C.
    Weiss, L.
    ANNALS OF ONCOLOGY, 2019, 30 : 27 - 27
  • [29] Real-world practice patterns and impact of PD-L1 expression testing in patients with advanced non-small cell lung cancer.
    Leapman, Michael
    Presley, Carolyn J.
    Zhu, Weiwei
    Soulos, Pamela R.
    Adelson, Kerin B.
    Boffa, Daniel J.
    Gross, Cary Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] First-line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer with 0-49% PD-L1: A Real-world Experience
    Benetti, B.
    Ferro, A.
    Girardi, F.
    Calvetti, L.
    Pavan, A.
    Mulargiu, C.
    Simionato, F.
    Pretelli, G.
    Lorenzi, M.
    Resi, M. V.
    Marinato, G.
    Dal Maso, A.
    Frega, S.
    Pasello, G.
    Aprile, G.
    Morandi, P.
    Guarneri, V.
    Bonanno, L.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S341 - S341
12345